- Home
- XBIT vs NBTX Comparison
XBIT vs NBTX Comparison
Compare XBIT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- NBTX
- Stock Information
- Founded
- XBIT 2005
- NBTX 2003
- Country
- XBIT United States
- NBTX France
- Employees
- XBIT N/A
- NBTX N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- XBIT Health Care
- NBTX Health Care
- Exchange
- XBIT Nasdaq
- NBTX Nasdaq
- Market Cap
- XBIT 217.5M
- NBTX 201.9M
- IPO Year
- XBIT 2015
- NBTX 2020
- Fundamental
- Price
- XBIT $6.66
- NBTX $3.89
- Analyst Decision
- XBIT
- NBTX Strong Buy
- Analyst Count
- XBIT 0
- NBTX 2
- Target Price
- XBIT N/A
- NBTX $11.50
- AVG Volume (30 Days)
- XBIT 54.9K
- NBTX 7.6K
- Earning Date
- XBIT 11-29-2024
- NBTX 11-26-2024
- Dividend Yield
- XBIT N/A
- NBTX N/A
- EPS Growth
- XBIT N/A
- NBTX N/A
- EPS
- XBIT N/A
- NBTX N/A
- Revenue
- XBIT N/A
- NBTX $45,220,186.00
- Revenue This Year
- XBIT N/A
- NBTX N/A
- Revenue Next Year
- XBIT N/A
- NBTX N/A
- P/E Ratio
- XBIT N/A
- NBTX N/A
- Revenue Growth
- XBIT N/A
- NBTX 526.17
- 52 Week Low
- XBIT $3.51
- NBTX $3.83
- 52 Week High
- XBIT $9.96
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- XBIT 41.29
- NBTX 40.72
- Support Level
- XBIT $6.68
- NBTX $3.83
- Resistance Level
- XBIT $7.43
- NBTX $4.55
- Average True Range (ATR)
- XBIT 0.54
- NBTX 0.23
- MACD
- XBIT -0.09
- NBTX -0.02
- Stochastic Oscillator
- XBIT 2.92
- NBTX 30.86
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.